Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 10

Cat.No. Product Name Information/Activity
BCC4374 Milrinone Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.
BCC6692 MMPX 78033-08-6
BCC6645 MY-5445 MY-5445 is a specific phosphodiesterase type 5 (PDE5) inhibitor. MY-5445 selectively inhibits cGMP PDE with a Ki of 1.3 μM.
BCC6215 Piclamilast 144035-83-6
BCC6638 Ro 20-1724 29925-17-5
BCC2282 Rolipram Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
BCC5429 (R)-(-)-Rolipram (R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is a selective inhibitor of phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
BCC2303 S- (+)-Rolipram (S)-(+)-Rolipram is a PDE4-inhibitor and an anti-inflammatory agent, less potent than its R enantiomer.
BCC7645 RS 25344 hydrochloride 152815-28-6
BCC6954 Siguazodan Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM.